Clinical Outcomes of Mechanical and Bioprosthetic Pulmonary Valve Replacement During Mid to Long-term Follow-up in a Single Tertiary Center for Congenital Heart Disease

Document Type : Original Article

Authors

1 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.

2 Cardiovascular Intervention Research Center Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.

3 Qazvin University of Medical Sciences, Qazvin, IR Iran.

Abstract

Background: Pulmonary valve replacement (PVR) is frequently performed during the correction of various congenital heart disease. Pulmonary valve substitutes include bioprostheses, homografts, and mechanical valves. Among these, bioprosthetic valves are probably the most widely used because they are readily available and they do not need lifelong anticoagulation therapy. However, most of these bioprostheses will fail and require replacement mainly due to structural valve degeneration.
 
Methods: We retrospectively identified all patients who had undergone PVR at Rajaie Cardiovascular Medical and Research Center between 2010 and 2017. Medical records were reviewed for demographic and clinical information and follow-up imaging results.
 
Results: A total of 435 patients were eligible, and they had regular follow-ups after PVR based on their medical records. Mechanical valves were used for 66% of the patients (n=288) at first PVR and bioprosthetic valves for 34% of the patients. Forty-five patients with mechanical pulmonary valves (15%) received at least 1 thrombolytic therapy due to prosthetic valve thrombosis. Seventeen patients needed redo PVR, and 28 patients (62%) had successful thrombolytic therapy. There was no significant association between redo PVR and the prosthetic valve size (P=0.7) or the valve type (P=0.07), although the percentage of patients with first bioprosthetic valves who needed redo PVR was almost twice that of patients with first mechanical valves (13.4% vs 5.9%).
 
Conclusions: A mechanical valve can be a promising option for PVR in selected patients. (Iranian Heart Journal 2021; 22(4): 66-70)

Keywords


  1. Husain SA, Brown J. Biologic versus Mechanical Valve Replacement of the Pulmonary Valve After Multiple Reconstructions of the RVOT Tract. Operative Techniques in Thoracic and Cardiovascular Surgery. 2006 Sep 1; 11(3):207-15.
  2. Freling HG, van Slooten YJ, van Melle JP, Ebels T, Hoendermis ES, Berger RM, Hillege HL, Waterbolk TW, van Veldhuisen DJ, Willems TP, Pieper PG. Pulmonary valve replacement: twenty-six years of experience with mechanical valvar prostheses. The Annals of thoracic surgery. 2015 Mar 1; 99(3):905-10.
  3. Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF. Braunwald's Heart Disease E-Book: A Textbook of Cardiovascular Medicine. Elsevier Health Sciences; 2018: pp.3657.
  4. Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier Health Sciences; 2015: pp.1507.
  5. Pragt H, van Melle JP, Javadikasgari H, Seo DM, Stulak JM, Knez I, Hörer J, Muñoz-Guijosa C, Dehaki MG, Shin HJ, Dearani JA. Mechanical valves in the pulmonary position: An international retrospective analysis. The Journal of thoracic and cardiovascular surgery. 2017 Oct 1; 154(4):1371-8.
  6. Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF. Braunwald's Heart Disease E-Book: A Textbook of Cardiovascular Medicine. Elsevier Health Sciences; 2018: pp. 3901.
  7. Chen XJ, Smith PB, Jaggers J, Lodge AJ. Bioprosthetic pulmonary valve replacement: contemporary analysis of a large, single-center series of 170 cases. The Journal of thoracic and cardiovascular surgery. 2013 Dec 1; 146(6):1461-6.
  8. Lee C, Park CS, Lee CH, Kwak JG, Kim SJ, Shim WS, Song JY, Choi EY, Lee SY. Durability of bioprosthetic valves in the pulmonary position: long-term follow-up of 181 implants in patients with congenital heart disease. The Journal of thoracic and cardiovascular surgery. 2011 Aug 1; 142(2):351-8.